Sunitix is an oncology product. It is used to treat cancer by preventing the activity of a special group of proteins which are known to be involved in the growth and spread of cancer cells.
Sunitix will only be prescribed by a doctor with experienced in the use of anti-cancer medicinal products.
Gastrointestinal stromal tumour (GIST)
Sunitinib is effective & safe in patients with advanced gastrointestinal stromal tumour after failure of imatinib treatment due to resistance or intolerance.
Sunitix is used for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
Metastatic renal cell carcinoma
Sunitix is used for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.
Pancreatic neuroendocrine tumours (pNET)
Sunitix is used for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.
It is limited to use Sunitinib as the first line treatment.
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
Registered and Licensed by Regulatory
Authority of Bangladesh
Sunitix is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh. Drug Registration Number: 00-000-000 Inclusion Date: 00-00-0000 Valid up to: 00-00-0000